MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%

MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy.

The study evaluated a once‑daily dosing regimen and failed to meet the predefined primary efficacy endpoint, marking a setback for the program.

Although secondary objectives were met and the company highlighted some encouraging signals, investors reacted sharply and the stock fell more than 60% after the announcement.